ERBB2 and non-small cell lung carcinoma: Within the MSKCC clinicogenomic cohort, patients with diverse ERBB2 activating mutations treated with various HER2 drug classes, including ADCs, experienced clinical responses in both NSCLC (54.5%) and non-NSCLC (26.7%) settings.